atosiban Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3008 | 90779-69-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Atosiban is a synthetic peptide which is a competitive antagonist of human oxytocin at receptor level. In human pre-term labour, atosiban at the recommended dosage antagonises uterine contractions and induces uterine quiescence.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 165 | mg | P |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 20, 2000 | EMA | Ferring Pharmaceuticals A/S |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Premature baby | 196.89 | 152.92 | 45 | 517 | 18067 | 46667433 |
| Foetal exposure during pregnancy | 187.98 | 152.92 | 48 | 514 | 30699 | 46654801 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02CX01 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Other gynecologicals |
| MeSH PA | D006727 | Hormone Antagonists |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D015149 | Tocolytic Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Prevention of Premature Labor | indication |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.81 | acidic |
| pKa2 | 12.85 | acidic |
| pKa3 | 13.13 | acidic |
| pKa4 | 13.53 | acidic |
| pKa5 | 13.54 | acidic |
| pKa6 | 13.87 | acidic |
| pKa7 | 9.93 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Oxytocin receptor | GPCR | ANTAGONIST | Ki | 7.96 | CHEMBL | DRUG LABEL | |||
| Vasopressin V2 receptor | GPCR | Ki | 6.48 | CHEMBL | |||||
| Vasopressin V1a receptor | GPCR | Ki | 9.82 | CHEMBL | |||||
| Vasopressin V1b receptor | GPCR | Ki | 7.36 | CHEMBL | |||||
| Oxytocin receptor | GPCR | Ki | 7.40 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 081D12SI0Z | UNII |
| D03008 | KEGG_DRUG |
| 914453-95-5 | SECONDARY_CAS_RN |
| C0164398 | UMLSCUI |
| CHEBI:135899 | CHEBI |
| CHEMBL382301 | ChEMBL_ID |
| DB09059 | DRUGBANK_ID |
| 5311010 | PUBCHEM_CID |
| 6392 | INN_ID |
| C047046 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2213 | IUPHAR_LIGAND_ID |
| 59639 | RXNORM |
| 008327 | NDDF |
| 008328 | NDDF |
| 326166008 | SNOMEDCT_US |
| 391792002 | SNOMEDCT_US |
| 427147004 | SNOMEDCT_US |
Pharmaceutical products:
None